



S F Schmitz

Contact

S F Schmitz

Publications (6)

Martinelli G, Zucca E, Dietrich P, Lohri A, Vorobiof H, Heizmann M, Stahel R, Stupp R, Okkinga E, Hess U, Cerny T, Utiger U, Schmitz S, Ghielmini M. Long term follow up of patients with follicular lymphoma receiving single agent rituximab at 2 different schedules in trial SAKK 35/98. *J Clin Oncol* 2010; 28:4480-4484.

Pichert G, Stahel R, Schmitter D, Stupp R, Betticher D, Cogliatti S, Cerny T, Hess U, Schmitz S, Ghielmini M. Weekly x 4 induction therapy with the anti-CD20 antibody rituximab: effect on circulating t(14;18)(+) follicular lymphoma cells. *Clinical lymphoma* 2001; 1:293-7.

Ghielmini M, Bertoni F, Schmitter D, Lohri A, Wernli M, Stupp R, Betticher D, Pichert G, Bürki K, Schmitz S, Cerny T. The effect of Rituximab on patients with follicular and mantle-cell lymphoma. Swiss Group for Clinical Cancer Research (SAKK). *Annals of oncology : official journal of the European Society for Medical Oncology / ESMO* 2000; 11 Suppl 1:123-6.

Cerny T, Brunner J, Sessa C, Honegger P, Schmitz S, Schaad R, Küpfer A, von Briel T, Leyvraz S, Boddy A. Saturable metabolism of continuous high-dose ifosfamide with mesna and GM-CSF: a pharmacokinetic study in advanced sarcoma patients. Swiss Group for Clinical Cancer Research (SAKK). *Annals of oncology : official journal of the European Society for Medical Oncology / ESMO* 1999; 10:1087-94.

Bernhard J, Goldhirsch A, Bonnefoi H, Fey M, Morant R, Cavalli F, Castiglione-Gertsch M, Schmitz S, Thürlimann B, Hürny C. Defining clinical benefit in postmenopausal patients with breast cancer under second-line endocrine treatment: does quality of life matter?. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology* 1999; 17:1672-9.

Bernhard J, Goldhirsch A, Bonnefoi H, Fey M, Morant R, Cavalli F, Thürlimann B, Schmitz S, Castiglione-Gertsch M, Hürny C. Quality of life in postmenopausal patients with breast cancer after failure of tamoxifen: formestane versus megestrol acetate as second-line hormonal treatment. Swiss Group for Clinical Cancer Research (SAKK). *European journal of cancer (Oxford, England : 1990)* 1999; 35:913-20.

Projects (0)

No results found.

Kantonsspital St.Gallen

Rorschacher Strasse 95

CH-9007 St.Gallen

T: +41 71 494 11 11

support.forschung@kssg.ch